Abstract

A CASE REPORT ON WALDENSTROM MACROGLOBULINEMIA

Kruti Joshi*, Khushi Shah, Dhruvi Patel and Priyanka J.

ABSTRACT

A monoclonal immunoglobulin M protein and lymphoplasmacytic cells infiltrate the bone marrow in Waldenström macroglobulinemia (WM), an indolent low-grade lymphoma. It is regarded as terminal. Patients with symptomatic WM have a 5-year survival rate of 87% for low-risk disease, 68% for intermediate-risk disease, and 36% for high-risk disease. Relative survival has increased as a result of recent advancements in therapy and new, tailored treatment choices. Understanding the significance of the WHIM-like CXCR4 and the MYD88 L265P mutations has been demonstrated, not only in terms of their diagnostic and prognostic utility but also as possible therapeutic targets. The average patient age at diagnosis is 71. Patients with WM might expect a long lifespan because it is not an aggressive disease. Anaemia is brought on by lymphoplasmacytoid cell infiltration of the bone marrow, which results in a number of issues, chiefly weariness, also possible are hepatomegaly, splenomegaly, and lymphadenopathy.

Keywords: Mutations, Waldenström macroglobulinemia, white blood cells, bone marrow, monoclonal antibodies, lymphoplasmacytoid.